
Treatment of hyperprolactinemic disorders, whether idiopathic or due to pituitary adenomas, in adult patients.
Not indicated for inhibition or suppression of physiologic postpartum lactation.
Initiate with 0.25 mg orally twice weekly.
Titrate incrementally by 0.25 mg twice weekly at intervals no less than 4 weeks to achieve normal serum prolactin levels.
Maximum recommended dose: 1 mg twice weekly.
Administer with or without food.
Evaluate cardiac valvular status via echocardiogram prior to initiation.
Cabergoline is a long-acting dopamine receptor agonist with high affinity for the D2 receptor. It is indicated for...
The annual cost of Cabergoline treatment is indeed a concern for many patients. Since the price of Cabergoline is...
Cabergoline is a dopamine receptor agonist primarily used in the treatment of various conditions associated with...
As an important medical drug, cabergoline plays a crucial role in the treatment of hyperprolactinemia caused by...
Cabergoline, as an important medical drug, is mainly used to treat conditions such as hyperprolactinemia caused by...
Cabergoline, as an important medical drug, plays a crucial role in the treatment of hyperprolactinemia and its...